

Supplementary Material

Real-world skin clearance and quality of life with risankizumab in patients with psoriasis with moderate skin involvement and those eligible for systemic therapy per International Psoriasis Council classification

Authors: Bruce Strober, MD, PhD^a, Manish Patel, Pharm D, MS^b, Mark I. Kaldas, Pharm D, MSc, MBA^b, Greg St John, PhD^b, Huzefa Photowala, PhD^b, Adam P. Sima, PhD^c, Thomas Eckmann, MPH^c, Alicia Beeghly, MPH, PhD^c, April Armstrong, MD, MPH^d

Affiliations: ^aYale University, New Haven, CT, and Central Connecticut Dermatology Research, Cromwell, CT, USA; ^bAbbVie Inc, North Chicago, IL, USA; ^cCorEvitas, LLC, Waltham, MA, USA; ^dUniversity of California, Los Angeles, Los Angeles, CA, USA

Corresponding author: Bruce Strober, MD, PhD

Department of Dermatology

Yale School of Medicine

333 Cedar Street

New Haven, CT 06510

Email: brucestrober30@me.com

Phone number: 203-432-4771

Fax: 203-737-4130

Supplementary Tables

Table S1. Details of additional Institutional Review Boards.

IRB Name	IRB reference number
Institutional Review Board University of Florida	IRB201901901
University Hospitals IRB	20180635
Tulane University Human Research Protection Office Institutional Review Boards	2019-1033
Mercy Health Corporation IRB	260
Health Research Ethics Board of Alberta	HREBA.CTC-20-0068_REN2
Health Research Ethics Board of Alberta	HREBA.CTC-21-0084
Health Research Ethics Board of Alberta	HREBA.CTC-21-0118_REN1
Health Research Ethics Board of Alberta	HREBA.CTC-21-0119_REN1
Health Research Ethics Board of Alberta	HREBA.CTC-22-0084
Veritas IRB	2022-1274-11737-1

IRB, Institutional Review Board.